{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,5]],"date-time":"2026-10-05T19:52:49Z","timestamp":1791229969828,"version":"4.1.0"},"reference-count":21,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"6","license":[{"start":{"date-parts":[[2026,2,6]],"date-time":"2026-02-06T00:00:00Z","timestamp":1770336000000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2026,2,6]]},"abstract":"<jats:p>To identify second primary malignancies (SPMs) death risk factors in prostate cancer (PCa) survivors and high-risk PCa patients for SPMs. With improved PCa survival, there\u2019s a growing need to study second SPMs in PCa survivors. PCa patients from 2004 to 2015 in the surveillance, epidemiology, and end results database were screened for SPM risk. The Fine and Gray competing risk model identified SPM mortality risk factors via univariate and multivariate analyses. A competing risk nomogram predicted 3-, 5-, and 10-year SPM mortality risk, stratifying patients by total scores for risk assessment. Model performance was assessed using the correlation index, receiver operating characteristic curve, calibration curve, and area under the curve. SPM-diagnosed PCa patients (2004\u20132015) were split into a 7:3 training (n\u2005=\u200531,435) and validation set (n\u2005=\u200513,472). The nomogram included 12 factors: age, chemotherapy, radiation, Gleason score, race, grade, marital status, tumor size, surgical site, surgery\/radiation sequence, scope, and stage. C\u2013index values were 0.70 (se: 0.001) and 0.684 (se: 0.002) in training and validation, respectively, indicating high discriminative power. The 3-, 5-, and 10-year area under the curves in training were 0.75 (95% confidence interval (CI): 0.72\u20130.77), 0.73 (95% CI: 0.72\u20130.75), and 0.72 (95% CI: 0.7\u20130.73), and in validation were 0.7 (95% CI: 0.65\u20130.74), 0.7 (95% CI: 0.67\u20130.73), and 0.71 (95% CI: 0.69\u20130.73), respectively, showing good predictive accuracy. The calibration curve confirmed model fit. A competing risk model predicts SPM mortality in PCa survivors, aiding high-risk patient identification and guiding survival-oriented treatment and follow-up strategies.<\/jats:p>","DOI":"10.1097\/md.0000000000047400","type":"journal-article","created":{"date-parts":[[2026,2,6]],"date-time":"2026-02-06T19:01:11Z","timestamp":1770404471000},"page":"e47400","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":1,"title":["Construction and validation of a competing risk model for specific survival of patients with second primary malignancies after prostate cancer"],"prefix":"10.1097","volume":"105","author":[{"given":"Er Hao","family":"Bao","sequence":"first","affiliation":[{"name":"Department of Urology, Sichuan Provincial People\u2019s Hospital East Sichuan Hospital & Dazhou First People\u2019s Hospital, Dazhou, Sichuan, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yang","family":"Yang","sequence":"additional","affiliation":[{"name":"Department of Traditional Chinese Medicine, Sichuan Provincial People\u2019s Hospital East Sichuan Hospital & Dazhou First People\u2019s Hospital, Dazhou, Sichuan, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jia Hao","family":"Wang","sequence":"additional","affiliation":[{"name":"Department of Urology, Nanchong Psychosomatic Hospital, Nanchong, Sichuan, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuchen","family":"Li","sequence":"additional","affiliation":[{"name":"Clinical Medical College, North Sichuan Medical College, Nanchong, Sichuan, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ying","family":"Liu","sequence":"additional","affiliation":[{"name":"Department of Urology, Affiliated Hospital of North Sichuan Medical College, Nanchong, Sichuan, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lin","family":"Yang","sequence":"additional","affiliation":[{"name":"Department of Urology, Affiliated Hospital of North Sichuan Medical College, Nanchong, Sichuan, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peng","family":"Hao","sequence":"additional","affiliation":[{"name":"Department of Urology, Dazhou Dachuan District People\u2019s Hospital (Dazhou Third People\u2019s Hospital), Dazhou, Sichuan, China."}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"R1-20260915","first-page":"363","article-title":"Cancer treatment and survivorship statistics, 2019.","volume":"69","author":"Miller","year":"2019","journal-title":"CA Cancer J Clin"},{"key":"R2-20260915","doi-asserted-by":"crossref","first-page":"e0227552","DOI":"10.1371\/journal.pone.0227552","article-title":"Overall survival and second primary malignancies in men with metastatic prostate cancer.","volume":"15","author":"Meht\u00e4l\u00e4","year":"2020","journal-title":"PLoS One"},{"key":"R3-20260915","doi-asserted-by":"crossref","first-page":"3734","DOI":"10.1200\/JCO.2012.41.8681","article-title":"Second malignant neoplasms: assessment and strategies for risk reduction.","volume":"30","author":"Wood","year":"2012","journal-title":"J. Clin. Oncol"},{"key":"R4-20260915","doi-asserted-by":"crossref","first-page":"356","DOI":"10.1016\/j.ejca.2018.07.005","article-title":"Cancer incidence and mortality patterns in Europe: estimates for 40 countries and 25 major cancers in 2018.","volume":"103","author":"Ferlay","year":"2018","journal-title":"Eur. J. Cancer"},{"key":"R5-20260915","first-page":"1358","article-title":"Multiple primary malignant tumors. A survey of the literature and a statistical study.","volume":"16","author":"Warren","year":"1932","journal-title":"Am J cancer"},{"key":"R6-20260915","doi-asserted-by":"crossref","first-page":"1808","DOI":"10.1002\/cncr.31247","article-title":"Temporal trends in the risk of second primary cancers among survivors of adult-onset cancers, 1980 through 2013: an Australian population-based study.","volume":"124","author":"Ye","year":"2018","journal-title":"Cancer"},{"key":"R7-20260915","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1007\/s12672-018-0330-0","article-title":"Risk of second primary female genital malignancies in women with breast cancer: a SEER analysis.","volume":"9","author":"Li","year":"2018","journal-title":"Horm Cancer"},{"key":"R8-20260915","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1016\/j.ajo.2016.02.022","article-title":"Second primary neoplasms in patients with uveal melanoma: a SEER database analysis.","volume":"165","author":"La\u00edns","year":"2016","journal-title":"Am J Ophthalmol"},{"key":"R9-20260915","doi-asserted-by":"crossref","first-page":"316","DOI":"10.1016\/j.clml.2019.12.017","article-title":"Survival of patients with second primary hodgkin lymphoma.","volume":"20","author":"Budnik","year":"2020","journal-title":"Clin Lymphoma Myeloma Leuk"},{"key":"R10-20260915","doi-asserted-by":"crossref","first-page":"1293","DOI":"10.1038\/s41598-020-80534-4","article-title":"Clinical characteristics and overall survival nomogram of second primary malignancies after prostate cancer, a SEER population-based study.","volume":"11","author":"Liu","year":"2021","journal-title":"Sci Rep"},{"key":"R11-20260915","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1016\/j.radonc.2010.09.012","article-title":"Analysis of second malignancies after modern radiotherapy versus prostatectomy for localized prostate cancer.","volume":"98","author":"Huang","year":"2011","journal-title":"Radiother Oncol"},{"key":"R12-20260915","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1016\/S0167-8140(02)00307-9","article-title":"The risk of second malignancy in men with prostate cancer treated with or without radiation in British Columbia, 1984-2000.","volume":"65","author":"Pickles","year":"2002","journal-title":"Radiother Oncol"},{"key":"R13-20260915","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1186\/s13014-016-0738-z","article-title":"Risk of second cancer following radiotherapy for prostate cancer: a population-based analysis.","volume":"12","author":"Hegemann","year":"2017","journal-title":"Radiat. Oncol"},{"key":"R14-20260915","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1007\/s00277-023-05095-8","article-title":"Second primary malignancies in non-Hodgkin lymphoma: epidemiology and risk factors.","volume":"102","author":"Zhan","year":"2023","journal-title":"Ann Hematol"},{"key":"R15-20260915","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1007\/s00432-019-03084-x","article-title":"Marital status independently predicts non-small cell lung cancer survival: a propensity-adjusted SEER database analysis.","volume":"146","author":"Chen","year":"2020","journal-title":"J Cancer Res Clin Oncol"},{"key":"R16-20260915","doi-asserted-by":"crossref","first-page":"1821","DOI":"10.1002\/cam4.758","article-title":"Marital status and survival in patients with gastric cancer.","volume":"5","author":"Jin","year":"2016","journal-title":"Cancer Med"},{"key":"R17-20260915","doi-asserted-by":"crossref","first-page":"913","DOI":"10.1007\/s10654-021-00781-1","article-title":"Marital status and prostate cancer incidence: a pooled analysis of 12 case-control studies from the PRACTICAL consortium.","volume":"36","author":"Salmon","year":"2021","journal-title":"Eur J Epidemiol"},{"key":"R18-20260915","doi-asserted-by":"crossref","first-page":"439","DOI":"10.1002\/cncr.22034","article-title":"Current status of lymph node-positive prostate cancer: incidence and predictors of outcome.","volume":"107","author":"Swanson","year":"2006","journal-title":"Cancer"},{"key":"R19-20260915","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1007\/s11934-017-0696-5","article-title":"Therapeutic value of standard versus extended pelvic lymph node dissection during radical prostatectomy for high-risk prostate cancer.","volume":"18","author":"Colicchia","year":"2017","journal-title":"Curr Urol Rep"},{"key":"R20-20260915","doi-asserted-by":"crossref","first-page":"1364","DOI":"10.1200\/JCO.2007.12.9791","article-title":"How to build and interpret a nomogram for cancer prognosis.","volume":"26","author":"Iasonos","year":"2008","journal-title":"J Clin Oncol"},{"key":"R21-20260915","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1038\/s41391-018-0089-y","article-title":"Impact of family history of cancer on risk and mortality of second cancers in patients with prostate cancer.","volume":"22","author":"Chattopadhyay","year":"2019","journal-title":"Prostate Cancer Prostatic Dis"}],"container-title":["Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.ovid.com\/10.1097\/MD.0000000000047400","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,15]],"date-time":"2026-09-15T18:02:36Z","timestamp":1789495356000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ovid.com\/10.1097\/MD.0000000000047400"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,2,6]]},"references-count":21,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2026]]}},"URL":"https:\/\/doi.org\/10.1097\/md.0000000000047400","relation":{},"ISSN":["0025-7974","1536-5964"],"issn-type":[{"value":"0025-7974","type":"print"},{"value":"1536-5964","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,2,6]]},"assertion":[{"value":"2025-05-20","name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-01-01","name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}}]}}